0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News and Perspectives |

Study Ignites Debate on New Anticoagulant

Mike Mitka, MSJ
JAMA. 2013;309(17):1763-1764. doi:10.1001/jama.2013.3857.
Text Size: A A A
Published online

Extract

San Francisco— Researchers claim that an experimental anticlotting drug that failed to demonstrate benefit in 2 previous studies showed positive results in a new study. They said the experimental drug, cangrelor, may offer another option for reducing periprocedural complications from percutaneous coronary intervention (PCI). But others are not so sure.

Current guidelines recommend that patients being considered for PCI receive dual antiplatelet therapy (aspirin and a platelet adenosine diphosphate–receptor antagonist, usually clopidogrel) to reduce the risk of developing stent thrombosis or myocardial infarction. But to achieve maximum benefit, clopidogrel, an oral agent, should be given 6 to 12 hours before PCI, and its antiplatelet effect can remain for days.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Experts are debating the potential role of an experimental anticlotting drug that has generated mixed results in clinical trials.

(Photo credit: Susumu Nishinaga/www.sciencesource.com)

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination
Clinical Scenario

brightcove.createExperiences();